TransMedics Group, Inc. $TMDX Shares Acquired by Yousif Capital Management LLC

Yousif Capital Management LLC increased its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 2.2% during the second quarter, Holdings Channel reports. The institutional investor owned 12,908 shares of the company’s stock after buying an additional 277 shares during the quarter. Yousif Capital Management LLC’s holdings in TransMedics Group were worth $1,730,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Vanguard Personalized Indexing Management LLC acquired a new position in TransMedics Group during the 2nd quarter worth approximately $286,000. SLT Holdings LLC purchased a new stake in shares of TransMedics Group during the 2nd quarter worth $334,000. Hager Investment Management Services LLC grew its stake in shares of TransMedics Group by 165.4% during the second quarter. Hager Investment Management Services LLC now owns 1,964 shares of the company’s stock worth $263,000 after purchasing an additional 1,224 shares in the last quarter. Maryland State Retirement & Pension System increased its holdings in TransMedics Group by 1.9% in the second quarter. Maryland State Retirement & Pension System now owns 9,943 shares of the company’s stock valued at $1,332,000 after buying an additional 185 shares during the last quarter. Finally, Valmark Advisers Inc. raised its stake in TransMedics Group by 34.6% in the second quarter. Valmark Advisers Inc. now owns 9,709 shares of the company’s stock valued at $1,301,000 after buying an additional 2,496 shares in the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. Wall Street Zen raised TransMedics Group from a “hold” rating to a “buy” rating in a research report on Saturday. Jefferies Financial Group assumed coverage on TransMedics Group in a research note on Monday, October 13th. They set a “buy” rating and a $145.00 target price for the company. Morgan Stanley upped their price target on TransMedics Group from $115.00 to $123.00 and gave the company an “equal weight” rating in a report on Friday, August 1st. Stifel Nicolaus initiated coverage on shares of TransMedics Group in a report on Thursday, September 4th. They set a “hold” rating and a $115.00 price objective on the stock. Finally, Weiss Ratings restated a “hold (c)” rating on shares of TransMedics Group in a research report on Wednesday, October 8th. Seven investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $127.18.

TransMedics Group Trading Up 1.7%

NASDAQ:TMDX opened at $117.63 on Monday. The company has a market capitalization of $4.01 billion, a PE ratio of 60.95 and a beta of 2.08. TransMedics Group, Inc. has a 52-week low of $55.00 and a 52-week high of $145.50. The stock’s 50 day moving average price is $116.52 and its 200 day moving average price is $113.94. The company has a quick ratio of 9.17, a current ratio of 9.86 and a debt-to-equity ratio of 1.61.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings data on Wednesday, July 30th. The company reported $0.92 earnings per share for the quarter, beating analysts’ consensus estimates of $0.48 by $0.44. The company had revenue of $157.37 million during the quarter, compared to analysts’ expectations of $146.64 million. TransMedics Group had a return on equity of 28.02% and a net margin of 13.49%.The firm’s revenue for the quarter was up 37.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.35 earnings per share. TransMedics Group has set its FY 2025 guidance at EPS. On average, research analysts anticipate that TransMedics Group, Inc. will post 1 EPS for the current year.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.